Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis

[1] Bisgaard TH(2022)Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment Nat Rev Gastro Hepat 19 717-726

[2] Allin KH(2013)Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study J Gastroen Hepatol 28 1148-1153

[3] Keefer L(2016)The Faroese IBD Study: Incidence of Inflammatory Bowel Diseases Across 54 Years of Population-based Data J Crohns Colitis 10 934-942

[4] Ananthakrishnan AN(2022)A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes Ther Adv Gastroenter 15 1098325649-87

[5] Jess T(2022)Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis Intest Res. 21 61-700

[6] Zeng Z(2015)Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs Expert Rev Gastroent 9 693-430

[7] Zhu Z(2023)A critical review of ustekinumab for the treatment of active ulcerative colitis in adults Expert Rev Gastroent 17 413-232

[8] Yang Y(2023)Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naive Patients with Ulcerative Colitis Digest Dis Sci 68 223-1780

[9] Ruan W(2014)Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3 Am J Gastroenterol 109 1771-1811

[10] Peng X(2005)Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study Gastroenterology 128 1805-1479

[1] Bisgaard TH(2022)Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment Nat Rev Gastro Hepat 19 717-726

[2] Allin KH(2013)Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study J Gastroen Hepatol 28 1148-1153

[3] Keefer L(2016)The Faroese IBD Study: Incidence of Inflammatory Bowel Diseases Across 54 Years of Population-based Data J Crohns Colitis 10 934-942

[4] Ananthakrishnan AN(2022)A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes Ther Adv Gastroenter 15 1098325649-87

[5] Jess T(2022)Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis Intest Res. 21 61-700

[6] Zeng Z(2015)Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs Expert Rev Gastroent 9 693-430

[7] Zhu Z(2023)A critical review of ustekinumab for the treatment of active ulcerative colitis in adults Expert Rev Gastroent 17 413-232

[8] Yang Y(2023)Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naive Patients with Ulcerative Colitis Digest Dis Sci 68 223-1780

[9] Ruan W(2014)Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3 Am J Gastroenterol 109 1771-1811

[10] Peng X(2005)Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study Gastroenterology 128 1805-1479